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Abstract: Cystic fibrosis (CF) is caused by mutations in the gene encoding the transmembrane
conductance regulator (CFTR) protein. Some CF patients are compound heterozygous or homozygous
for nonsense mutations in the CFTR gene. This implies the presence in the transcript of premature
termination codons (PTCs) responsible for a truncated CFTR protein and a more severe form
of the disease. Aminoglycoside and PTC124 derivatives have been used for the read-through
of PTCs to restore the full-length CFTR protein. However, in a precision medicine framework,
the CRISPR/dCas13b-based molecular tool “REPAIRv2” (RNA Editing for Programmable A to I
Replacement, version 2) could be a good alternative to restore the full-length CFTR protein. This RNA
editing approach is based on the targeting of the deaminase domain of the hADAR2 enzyme fused to
the dCas13b protein to a specific adenosine to be edited to inosine in the mutant mRNA. Targeting
specificity is allowed by a guide RNA (gRNA) complementarily to the target region and recognized
by the dCas13b protein. Here, we used the REPAIRv2 platform to edit the UGA PTC to UGG in
different cell types, namely IB3-1 cells, HeLa, and FRT cells engineered to express H2BGFPopal and
CFTRW1282X, respectively.
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1. Introduction
Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane
conductance regulator (CFTR) protein, an ATP-gated anion channel, which plays a major role in
regulating both secretion and absorption in many epithelial tissues [1]. Nonsense mutations in the CFTR
gene generate premature termination codons (PTCs), leading to premature translation termination and
causing the synthesis of a truncated non-functional CFTR protein.
Approximately 8% of CF patients worldwide and 13% in Europe were reported to be compound
heterozygous or homozygous for a nonsense mutation and the percentage of these patients was
remarkably high in Israel (Ashkenazi 45.5%), Italy (32.4%), and Slovenia (27.3%) [2].
These patients could take advantage of a drug treatment promoting the translation read-through
of the PTC to restore the CFTR full-length protein, at least to some extent. In the past, aminoglycoside
antibiotics (e.g., G418) were used for the read-through approach since they affect the proofreading
function of the ribosome [3]. However, prolonged treatments with aminoglycosides cause severe side
effects [4], thus their clinical use has been limited. New aminoglycosides like NB30 and NB54, as
well as the unrelated chemical compound PTC124, have been reported to promote the read-through
of PTCs, likely leading to the insertion of a near-cognate amino acid at the PTC site in the CFTR
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protein [5,6]. However, PTC124 (also known as Ataluren) has been discontinued as a potential drug
to treat FC after phase 3 trial and failure to restore CFTR in organoids [7]. Recently, some small
molecules, PTC124 derivatives that do not show the toxicity of aminoglycosides, have been suggested
as a potential treatment for genetic disorders caused by nonsense mutations [8–13].
Although the development of drugs aimed to overcome nonsense mutations appears
promising [11,12], it cannot be ruled out the possibility that they introduce a non-cognate amino acid,
which impairs full-length protein function. Thus, novel approaches based on site-directed RNA editing
(SDRE) to restore the full-length functional protein are worth to be investigated.
Different SDRE promising platforms have been reported in recent literature [14–17]. Some are based
on recruitment of native adenosine deaminases acting on RNA (ADARs) by antisense oligonucleotides
(ASOs) [18–20], others on the recruitment of exogenous recombinant ADARs via the fusion to an RNA
guide recognizing domain. The RNA guide hybridizes to the target region where the deaminases are
thus conveyed [21,22].
The Rosenthal lab [23] first reported the use of SDRE to correct the CFTR mRNA with the W496X
nonsense mutation injected into Xenopus oocytes.
In the era of personalized medicine, the CRISPR (classes of regularly interspaced short palindromic
repeats) and CAS (CRISPR-associated) nuclease systems are considered valuable tools for novel
therapeutics’ approaches [24]. Recently, the Feng Zhang lab pointed out the possibility of editing
mRNA at the level of specific stop mutations before it undergoes translation. This has been made
possible by exploiting the deaminase domain (DD) of the human ADAR2 [25]. Human ADAR2 changes
adenosine (A) into inosine (I) by hydrolytic deamination. By this novel technology, the “RNA Editing for
Programmable A to I Replacement, version 2” (REPAIRv2), editing is achieved by directing the ADAR2DD
(E488Q/T375G) to mutant mRNAs by the catalytically inactive CRISPR-associated RNA-guided RNase
Cas13b (dCas13b) and a 25–80-nucleotides-long specific guide RNA (gRNA). Editing the adenosine of
the PTC (UGA) to inosine would correct the nonsense mutation since the ribosomal machinery reads
inosine as guanosine. Thus, for mutations involving a G>A transition, deamination can restore a sense
codon or even the WT coding sequence in place of a premature stop codon.
A concern of ADAR’s overexpression is that the system could be associated to a higher risk
of off-target activity, which is still a major issue in SDRE [26]. However, the REPAIRv2 platform
was able to reduce the detectable off-target edits from about 8500 (λN-BoxB) to only 20 in the whole
transcriptome [15], providing higher specificity than previously described RNA editing platforms.
It is important to remark that, in contrast to DNA editing whose off-target effects are unpredictable
and potentially hazardous, RNA editing is transient, can be more easily reversed, allowing a better
control over editing outcomes, and it does not require the presence, at the targeting sites, of a protospacer
adjacent motif (PAM) [27].
Here, we evaluated the REPAIRv2 platform efficacy in editing the UGA premature termination
codon in the H2BGFPopal reporter gene [28] and in the CFTRW1282X cDNA. We first targeted an UGA
PTC that was previously introduced in the transcript coding for the H2B histone tagged with the green
fluorescent protein (H2BGFP) expressed in engineered HeLa cells (HeLa-H2BGFPopal) [10], where it
decorates the chromosomes in green [29]. We then introduced the W1282X nonsense mutation in the
CFTR cDNA and then engineered Fischer Rat Thyroid cells (FRT-CFTRW1282X) as a model to edit the
CFTR transcript and restore the full-length protein. Furthermore, we edited the naturally occurring
nonsense mutation in human IB3-1 airway epithelial cells (compound heterozygous F508del/W1282X)
that do not express any detectable amounts of endogenous CFTR protein [30].
2. Results
2.1. ‘Spacer’ Design and Cloning into the Vector pC0043-PspCas13b
The catalytic domain of the hADAR2 deaminase (ADAR2DD) is fused to the dCas13b protein
necessary for the recognition of the specific target. To address the dCAS13b/ADAR2DD fusion protein
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to the target mRNA, cells must also express a guide RNA (gRNA). The gRNA is composed of a spacer, a
specific sequence complementary to the mRNA region surrounding the adenine to be deaminated,
which is recognized by a C:A mismatch, followed by a scaffold, a sequence that folds to create the
recognition hairpin for dCas13b (Figure 1).
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Figure 1. Schematic representation of mRNA editing by REPAIRv2; sgRNA: Specific guide RNA. The
C:A mismatch at the target position and the outcome of editing, A to I replacement in the mRNA,
are shown.
Spacers were obtained by annealing two synthetic complementary single-strand oligonucleotides
30 and 50 bases long, considering that spacers’ length could affect editing [25]. The C base at the target
position in the forward oligo (or antisense strand) was introduced at different distances from the 3′
end of the spacer and, thus, from the 5′ end of the scaffold, to generate the C:A mismatch in the hybrid
gRNA/mRNA. This distance between the target adenin and he first nucleotide of the sc ffold, indeed,
seems to affect the recogn t e correct adenine to target and, c nsequently, the precision f the
editing. Finally, i the 5′ position of the spacer we made sure to have a guanine, which is important to
enhance the transcription from the U6 promoter, and to have different 5′ overhangs allowing directional
cloning [25].
We first aimed at targeting the premature stop codon TGA that causes the mutation W190X in the
H2BGFP protein [10]. Editing the mRNA by changing the UGA into UGI is supposed to restore the
tryptophan at position 190 in the polypeptide chain, suppressing the nonsense mutation. Four sets
of complementary oligonucleotides were designed to obtain specific spacers to target the adenine at
position 570 of the H2B-GFPopal cDNA. Three spacers were 50 bases l ng and the dista ce of the
mismatch position from t e 3′ ends was of 32, 34, or 35 nuc lotides (nts), respectively. The l st spacer
was 30 bases long and the distance of the ismatch was of 25 nts (Supplementary Figure S1A–D).
The same approach was used to target the W1282X opal nonsense mutation (UGG>UGA, g3846a) in
the CFTR mRNA. To this aim, we designed three different 50-nucleotides-long spacers, complementary
to the region surrounding the W1282X mutation. In the gRNA/mRNA hybrid the distance of the C:A
mismatch from 3′ end of the spacer was of 32, 34, and 35 nts (Supplementary Figure S2A–C).
The annealed complementary oligonucleotides were cloned into the BbsI sites of PspCas13b crispr
RNA (crRNA) backbone vector (Addgene) upstream of the scaffold sequence, under the control of
the U6 promoter (Figure S3). Positive clones were selected by colony PCR with different couples of
primers for GFP gRNA clones and CFTR gRNA clones (Supplementary Figure S4A,B).
2.2. Evaluation by Fluorescence Microscopy of RNA Editing of the H2BGFPopal Stop Mutation
The HeLa-H2BGFPopal cells were transiently transfected with the dCas13b/ADAR2DD plasmid
and with the plasmid carrying specific GFP guide RNAs. To optimize the experimental procedure, we
did several transfections varying the amount of the two plasmids, maintaining the 2:1 ratio (gRNA:
dCAS13b/ADAR2DD). After 48 h from the transfection, cells were fixed and observed at the fluorescence
microscope. Green fluorescence was observed both in the nuclei of HeLa H2BGFPWT cells, as expected,
and in the transfected HeLa H2BGFPopal cells, although in these cells the fluorescence appeared less
bright (Figure 2).
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DAPI (blue). HeLa H2BGFPWT cells and untransfected H2BGFPopal cells were used as positive and 
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The modest level of editing observed in these experiments could be explained by the low 
co-transfection efficiency of the REPAIRv2 system plasmids. Thus, in the attempt to increase the 
Figure 2. luorescence analysis to detect editing f t e PTC (UGA) in H La cell expr ssing the
H2BGFPopal gene. HeLa-H2BGFPopal cells were co-transfected with dCAS13b/ADAR2DD and selected
gRNAs coding plasmids (450 ng total DNA). Two days after transfection, cells were fixed with
methanol for 5 min and the green fluorescence due to H2BGFP expression was monitored using the
63X objective on a ZEISS microscope equipped for epifluorescence. Nuclei were visual z d with DAPI
(blue). HeLa H2BGFPWT cells and untransfected H2BGFPopal cells were used as positive and negative
control, respectively.
The modest level of editing observed in these experiments could be explained by the low
co-transfection efficiency of the REPAIRv2 system plasmids. Thus, in the attempt to increase the
chance of editing the UGA premature termination codon by the REPAIRv2 system, we generated
HeLa-H2BGFPopal cells stably expressing dCAS13b/ADAR2DD. After transfection with selected gRNAs
coding plasmids, green fluorescence was brighter than in the cells transfected with both plasmids in
transient. H2BGFP was detectable in HeLa-H2BGFPopal cells, in particular in those transfected with the
GFP gRNAs 50–34 or 50–35 clones, though to a lesser extent than in HeLa-H2BGFPWT used as control.
Lower GFP fluorescence was detected in HeLa-H2BGFPopal cells expressing the gRNAs 50–32 or 30–25
(Figure 3).
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Figure 3. Fluorescence analysis after editing the PTC (UGA) in HeLa-H2BGFPopal cells stably expressing
dCAS13b/ADAR2DD. HeLa cells stably expressing dCAS13b/ADAR2DD were transfected with selected
gRNAs coding plasmids (300 ng of total DNA). Two days after transfection, cells were fixed with
methanol for 5 min and the H2BGFP (g een) was d tected sing the 63x objective on a ZEISS microscope
equipped for epifluorescence. Nuclei were stained with DAPI (blue). HeLa-H2BGFPWT cells and
untransfected HeLa-H2BGFPopal cells, expressing dCAS13b/ADAR2DD, were used as positive and
negative control, respectively.
A difference in editing efficacy of different guides can be expected since, as stated above (Section 2.1),
it is known that the distance of the target adenine from 3′ end of the spacer may affect the ability of
the ADAR deaminase to contact it. Following our observations, for the experiments described in the
next sections we used 50-nucleotides-long gRNAs with the mismatch distances from 3′ end of 34 and
32 nucleotides (gRNA 50–34 and a gRNA 50–32, respectively) that, at least in the case of H2BGFPopal
mRNA, seemed to give better results.
Another factor that could affect the level of editing is the amount of the target mRNA to be edited
in the cells. Indeed, in these cells we observed that mRNA with nonsense codon is less abundant
than the WT (Figure 4). Although here H2BGFPopal is expressed from a cDNA and it is not subjected
to splicing, and thus not controlled by nonsense-mediated decay (NMD) [31], its mRNA probably
undergoes the mRNA no-go decay (NGD) surveillance pathway that is triggered when ribosomes stall
on damaged mRNA or an mRNA harboring a PTC [32,33].
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2.3. Editing of the CFTR Transcripts with UGA Nonsense Mutation in FRT-CFTRW1282X Cells
To evaluate the efficacy of the REPAIRv2 system on CFTR transcript with PTC, we used the
engineered FRT epithelial cells, which do not express endogenous cyclic AMP (cAMP)-regulated
chloride (Cl-) channels [34], stably transfected with a plasmid encoding a nonsense mutant CFTR
transcript (CFTRW1282X). To this aim, in the full-length CFTR cDNA that is cloned in the pTracer
plasmid (pTCF-WT) [34,35], we introduced a premature stop codon (TGG>TGA) in place of the
Tryptophan 1282-coding codon (W1282) by site-directed mutagenesis. By colony PCR, we isolated a
positive bacterial clone. Purified plasmid DNA was verified by sequencing (Figure S5A,B) and then
stably transfected in FRT cells. The amount of the CFTRW1282X mutant transcript, representing the
target for editing in FRT-CFTR W1282X cells, was assessed by RT-qPCR and it was less than 40% of the
CFTRWT transcript (Figure 5). The reduction of this transcript harboring a PTC was probably caused
by the NGD pathway, as suggested above.
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To edit the mutant mRNA and rescue the full-length CFTR protein, FRT-CFTRW1282X cells were
transfected with plasmids coding for the dCas13b/ADAR2DD fusion protein and with selected CFTR
gRNAs. To optimize the experimental procedure, we did several transfections, varying the amount of
the two plasmids, always maintaining the 2:1 ratio (gRNA:dCAS13b). The CFTR protein was then
detected using different antibodies: mAbCF3, targeting the extracellular loop of CFTR, and mAb570,
targeting the intracellular R domain of the protein. With the aim to enhance the antibody entry into the
cells and epitope binding, cells fixed with methanol were further permeabilized with triton treatment
before the incubation with mAb570. However, as shown in Figures S6 and S7, no significant difference
was observed when only methanol fixation was performed. We detected positive cells for the CFTR
protein by immunofluorescence microscopy (Figures 6 and 7A), suggesting that there the amount of
the CFTRW1282X transcript was enough for the REPAIRv2 tool to work. First, cells were transfected
with the dCAS13b/ADARDD vector and single CFTR gRNA 50–34 clone (Figure 6).
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Next, in the attempt to maximize the editing, we simultaneously transfected the cells with both
CFTR gRNAs 50–34 and 50–32, maintaining the 2:1 ratio (gRNA:dCAS13b/ADAR2DD). As shown in
Figure 7A,B, the number of positive cells was appreciably higher if compared with the transfections
with a single gRNA plasmid.
These results show that although the amount of target CFTR’s mutant mRNA is low, the REPAIRv2
system provided enough editing to allow the rescue of the CFTR protein, at least in some cells.
2.4. Evaluation of CFTR Rescue Following Editing CFTRW1282X in IB3-1 Human Cells
Encouraged by the results obtained with FRT-CFTRW1282X cells, we then evaluated if the REPAIRv2
system could be able to edit the endogenous CFTRW1282X mutation present in IB3-1 airway epithelial
cells (compound heterozygous F508del/W1282X) that do not express any detectable amounts of
endogenous CFTR protein [30].
By using REPAIRv2 in IB3-1 airway epithelial cells, the recovery of CFTR protein will only be the
result of the UGA>UGG conversion by RNA editing, since, to correct the F508del CFTR mRNA, it
would be necessary to insert a triplet in the mutant transcript, a task that this technology is unable
to do.
Taking advantage of our previous results, we performed transfections with two CFTR gRNAs’
clones, 50–32 and/or 50–34, at two different concentrations and we then detected the CFTR protein with
the specific antibody mAb570 by immunofluorescence microscopy. Different from what we observed
in the experiments using FRT-CFTRW1282X, the majority of IB3-1 cells were fluorescent, indicating the
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Figure 8. Immunofluorescence analysis to detect the CFTR protein in triton permeabilized IB3-1 cells
and quantification of the immunofluorescence. IB3-1 cells were untreated (NT: Negative control),
treated with G418 (positive control), or transfected with the plasmids encoding the 50-32/5034 gRNAs
and dCAS13b/ADAR2DD. (A) CFTR protein was revealed by the specific primary antibody mAb570 and
a secondary antibody (green, Alexa-488, Abcam). Nuclei (blue) were DAPI stained. Images were taken
at 63x agnification on a ZEISS microscope equipped for epifluorescence. (B) The quantification is
relative to the replicate repr sen ativ of th r sults. The rror bar represents the SEM. The quantification
of CFTR signal was done manually by using Fiji software. The cell contour was drawn by using a cell
membrane marker. The background was subtracted and the pixel mean in the selected area (one cell)
was measured.
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2.5. Visualization of Editing by cDNA Sequencing
Forty-eight hours after cell transfection with Cas13b/ADAR2DD vector and gRNA clones, total RNA
was extracted and retrotranscribed. The cDNAs were then amplified with primers surrounding the
mutant position and sequenced (BMR genomics) to verify if any editing occurred. In the case of
effective editing, we expected to see a double A/G peak at the mutant position in the electropherograms.
Representative experiments with HeLa-H2BGFPopal cells and FTR-CFTRW1282X are shown here. To edit
the UGA PTC, the two cell lines were transfected with dCas13b/ADAR2DD vector and plasmids
encoding GFP gRNA 50–34 or 50–35 and CFTR gRNA 50–34, respectively. Following RNA extraction,
retrotranscription, and PCR amplification, by standard sequencing we were unable to detect a double
A/G peak at target positions in the electropherograms of H2BGFPopal reporter gene (Figure 9A,B) and
CFTRW1282X (Figure 9C).
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Thus, it seems necessary to get at least ~30% of edited transcript in the cell to visualize a significant
G peak in the electropherogram by standard DNA sequencing.
3. Discus ion
We used the REPAIRv2 tool to edit a premat codon (UGA) in different cell models with
the aim of recovering full-length proteins. ollecti ely, our results suggest, for the first time to our
knowledge, that the REPAIRv2 tool is able to edit the UGA premature stop codon present in the
HeLa-H2BGFPopal and FRT-CFTRW1282X engineered cells, as well as the UGA premature stop codon
present in IB3-1CF human airway epithelial cells (CFTR F508del/W1282X).
However, following editing assays, we detected a moderate-intensity signal of direct
green fluorescence in a small number of HeLa-H2BGFPopal cells and of immunofluorescence in
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FRT-CFTRW1282X. Moreover, standard DNA sequencing technique was unable to detect TGA>TGG
conversion, as revealed by the absence of the expected double A/G peak at target position,
in Hela-H2BGFPopal and FRT-CFTRW1282X cells. This result suggests that the total amount of edited
transcript was likely under the threshold of sensitivity of the technique. In fact, we observed the
expected double peak with a 2:1 ratio (WT:mutant amplicons), indicating that it is necessary to get
at least 30% of edited transcript to visualize the G peak in the electropherogram by standard DNA
sequencing. These results reflect both the transfection efficiency, which is usually around 20–30%,
and the low level of nonsense transcript in engineered cells, which could also differ cell by cell.
Indeed, in these cells, H2BGFPopal and CFTRW1282X nonsense mRNAs probably underwent the mRNA
NGD pathway.
In IB3-1 cells, the transcript encoded from the CFTR allele with the W1282X nonsense mutation
was degraded by the nonsense-mediated decay (NMD) pathway [31], protecting cells from translation
of the mutant transcript, but here CFTRW1282X mRNA was endogenously expressed. Indeed, we could
see a signal indicating rescued CFTR in more cells than in FRT cells. Nevertheless, it was still not
possible to quantify the CFTR protein by Western blot (data not shown).
Considering the complexity of the REPAIRv2 technique, we think that the number of cells
that undergo the mRNA editing, which are detected by IF or direct fluorescence, was likely not
enough to obtain a CFTR or H2BGFP protein amount to be detected by Western blot in total extracts.
A full-length H2BGFP protein from H2BGFPopal HeLa cells was detected by Western blot, but only after
immunoprecipitation with anti-GFP antibody (Figure S8A,B). Anyway, the immunofluorescence results
highlighted by the IF images’ quantification of FRT-CFTRW1282X and IB3-1 cells (Figures 7B and 8B)
suggest that editing of the UGA premature termination codon in these cells resulted in the partial
restoration of the CFTR protein. In addition, it seems that rescued CFTR properly localized onto
the plasma membrane. However, it remains to be determined if the protein’s channel function
was recovered.
From our results, we could not reason about the eventual off-target activity, which will need to be
rigorously investigated in the future. However, one of the most attractive features of REPAIRv2 is the
use of mutant hADAR2DD (E488Q/T375G), which showed the highest level of editing associated with
the lowest numbers of transcriptome-wide off targets when compared to other RNA editing approaches.
Finally, though transcript editing seems to be modest, by looking at the immunofluorescence
results, we believe that the REPAIRv2 system is potentially suitable for the correction of UGA PTC
present in CFTRW1282X transcript and we hypothesize that the REPAIRv2 editing tool could get
advantage by reagents that increase/stabilize the transcript to be edited.
4. Materials and Methods
4.1. Site-Directed Mutagenesis and Bacterial Clone Selection
Site-directed mutagenesis was performed with the Quick change II site-directed-mutagenesis
kit (Agilent) based on a few rounds of PCR amplification of the plasmid harboring target DNA
with a high-fidelity DNA polymerase and the following couple of complementary mutant primers:
W1282Xop-dw and W1282Xop-up. Unmethylated, newly synthesized plasmids were transformed into
super-competent XL1Blue bacterial strain. Colonies harboring the pTracer-CFTRW1282X were identified
by colony PCR with primers CFTRdw3 and CFTRup4. Plasmid DNA was purified from a positive
colony and sequenced with primer CFTRup4. Nucleotide substitution g3846a was confirmed by DNA
sequencing (BMR genomics). Oligonucleotides used in this subsection are listed in Table S1.
4.2. Vectors and Clones Used in This Study
The sequence coding for the fusion protein was expressed from the
CMV-dPspCas13b-GS-ADAR2DD (E488Q/T375G)-delta-984-1090 vector (Addgene). The specific gRNA
was transcribed under the control of the U6 promoter after cloning the DNA fragment coding for
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the spacer into the PspCas13b crRNA backbone vector (Addgene), upstream of the hairpin coding
sequence (Figure S3).
4.3. Spacer Cloning
The complementary oligonucleotides to be annealed, and subsequently cloned in PspCas13b
crRNA backbone vector, were heated up to 94 ◦C and then allowed to cool down to room temperature
in a medium salt buffer. After digestion with BbsI restriction enzyme and agarose gel purification,
the PspCas13b crRNA backbone vector was ligated by T4 ligase with each of the DNA fragments
separately and then transformed into XL1 Blue bacterial competent strain. Positive clones were selected
by colony PCR with the primer pUC-M13 Rev coupled with GFP 3′G wt for GFP gRNA clones or
−40 forw for CFTR gRNA clones. Plasmid DNA of clones selected for further characterization was
extracted by a commercial kit (Invitrogen or Qiagen), gel verified, and sequenced with M13 Rev primer
(BMR genomics). Oligonucleotides used to generate gRNA coding fragments are listed in Table S2.
Oligonucleotides used for colony PCR and sequencing are listed in Table S3.
4.4. Cell Culture Conditions
The IB3-1 is a bronchial cell line derived from a cystic fibrosis patient with a F508del/W1282X
CFTR genotype. IB3-1 and HeLa cells were cultured in Dulbecco's Modified Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 µg/mL streptomycin,
and 1 mM sodium pyruvate. Fisher Rat Thyroid (FRT) cells were cultured in Coon’s modified F12
medium supplemented with 10% FBS, 2 mM glutamine, and 2.68 g/L sodium bicarbonate. Cells were
grown in a humidified atmosphere of 5% CO2 in air at 37 ◦C.
4.5. Cell Transfection
HeLa-H2BGFP, FRT-CFTR, and IB3-1 cells grown on ibidi™ flasks were co-transfected at 90%
confluency by Lipofectamine 3000 (Invitrogen) with plasmids coding for the different guide RNAs
and the plasmid coding for dCAS13b/ADAR2DD. The ratio DNA/number of cells was calculated in
accordance with the Lipofectamine 3000 protocol (Invitrogen). We transfected 300 or 450 ng of total
DNA in HeLa cells and 150 or 300 ng of total DNA in FRT and IB3-1 cells, always maintaining the ratio
2:1 of gRNA:CAS13b/ADAR2DD, also when guides where used in combination.
4.6. Immunofluorescence
Forty-eight h post transfection, cells were fixed with methanol for 5′ and, when specified, they
were further permeabilized with Triton 0.01% for 10′ a room temperature. Cells were then blocked
with bovine serum albumin (BSA) 0.1% at R.T. for 30′ and incubated with the mAb570 (provided by
the University of North Caroline) or the mAbCF3 (mAb 2784 Abcam) and diluted 1:500 in BSA 0.1%
overnight at 4 ◦C. They were finally incubated with secondary anti-mouse mAb (FITC-conjugated,
Sigma, diluted 1:300 or Alexa 488, Abcam, diluted 1:500) for 1 h at room temperature before DAPI
staining and microscopy observation. The exposure time was adjusted using the negative control as
reference (no fluorescence signal observed).
4.7. RT-qPCR
Total RNA was extracted by using the RNAeasy Mini Kit (Qiagen) and retrotranscribed with
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystem). The cDNAs (50 ng/replicate)
were then added to a mix containing SYBRTM Green (Applied Biosystems; 12,5 µL/replicate),
H2O, for a final volume of 20 µL/well and forward and reverse primers 1 µM each (CFTRdw10
5′acttctaatggtgatgacagcc3′/CFTRup9 5′-atccagcaaccgccaacaact3′; GFP-F 5’agaacggcatcaaggtgaac3’/
GFP-R 5’tgctcaggtagtggttgtcg3’). Samples were analyzed with the thermocycler Applied Biosystems
7300 Real Time PCR System 96-well qPCR (15” at 95 ◦C, 60” at 60 ◦C, for 40 cycles) [36,37].
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4.8. The cDNA Synthesis and RT-PCR
The cDNAs were amplified by standard PCR with specific primers annealing to sequences
close to the editing target site. The cDNAs from HeLa- and FRT-transfected cells were amplified
with GFPdown/GFPrev and CFTRdw3/CFTRup4 couples of primers, respectively. Sequencing was
performed by BMR genomics with GFPrev or CFTRdw3 primers. Primers are listed in Tables S1 and S3.
4.9. Western Blotting and Immunoprecipitation
Two days after transfection, HeLa-H2BGFPopal cells were lysated with RIPA Lysis and Extraction
buffer (ThermoFisher Scientific, MA, USA) as previously described [38–40]. Then, 20 µg of total
proteins were separated on a 10% polyacrylamide (SDS-PAGE) and transferred onto a nitrocellulose
membrane. Membrane was then blocked with 5% milk in tween tris-buffered saline (T-TBS) solution for
1 h at room temperature and incubated overnight at 4 ◦C with a mouse monoclonal antibody anti GFP
(1:1000) (Santa Cruz, CA, USA). Following incubation with an anti-mouse peroxidase-linked antibody
(1:5000), the reaction was revealed by the enhanced chemiluminescence (ECL) detection system, using
chemidoc imaging system (Biorad). For the immunoprecipitation, the total cellular lysates from two
independent experiments were pooled and dialyzed against H2O for 48 h at 4 ◦C. Dynabeads® (3 mg)
were incubated with the mouse monoclonal antibody anti-GFP (10 µg) in phosphate buffered saline
(PBS) (pH 7.4) with 0.01% Tween®-20 for 1 h under rotation. The proteins were incubated with rotation
for 1 h at room temperature with the Dynabeads®-Ab complex. Surnatants (unbound) and proteins
eluted off the beads (bound) were separated on an 8% polyacrylamide gels (SDS-PAGE), transferred
onto a nitrocellulose membrane, and analyzed by Western blotting as above.
4.10. Quantifications of the Immunofluorescence
The quantifications of immunofluorescence experiments were relative to the replicate
representative of the results. Quantification of CFTR signal was done manually by using Fiji. Briefly,
the cell contour was drawn by using a cell membrane marker. The background was subtracted and the
integrated signal intensity or the pixel mean in the selected area (one cell) was measured.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/13/4781/
s1. Figure S1: Spacer sequences for H2BGFPopal (W190X) editing. Figure S2: Spacer sequences for CFTRW1282X
editing. Figure S3: Vectors for CRISPR-based RNA editing. Figure S4: Colony PCR to select positive GFP and
CFTR gRNA clones. Figure S5: Site-directed mutagenesis. Figure S6: Immunofluorescence analysis of CFTR
protein in sole methanol fixed FRT-CFTRW1282X cells and quantification of the immunofluorescence. Figure S7:
Immunofluorescence analysis to detect the CFTR protein in in sole methanol fixed IB3-1 cells and quantification
of the immunofluorescence. Figure S8: Western blotting analysis to detect H2BGFP protein after editing of the
PTC (UGA) in H2BGFPopal mRNA expressed in HeLa cells. Table S1: Oligonucleotides used for site-directed
mutagenesis, colony PCR, and sequencing described in Section 4.1. Table S2: Oligonucleotides used to generate
gRNA coding fragments. Table S3: Oligonucleotides used for colony PCR and sequencing described in Section 4.3
and RT-PCR in Section 4.7.
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